2019 IN NUMBERS

R&D portfolio

- 46 R&D projects
- 23 new chemical entities in DNDi’s drug development pipeline
- >350,000 chemical compounds screened for new drug potential

Clinical trials

- 18 clinical trials in 6 disease areas at 59 sites in 20 countries
- 2,710 patients enrolled in active DNDi clinical studies
- 51% of patients enrolled are children

Maximizing the virtual model

- 4.7:1 ratio of partner vs DNDi FTEs*
- 15:1 ratio of partner vs DNDi FTEs* in Africa

Support received

- EUR 51.4 MILLION in multi-year funds secured
- EUR 6.2 MILLION in-kind contributions and collaborative funding from partners

Sharing knowledge

- 45 peer-reviewed scientific publications on DNDi’s research
- 96% published in open-access journals
- 50% had a female lead or co-lead author
- 76% had at least one author from a partner institution in an endemic country

Strengthening capacities

- 630 people trained to support clinical research in Africa, Asia, and Latin America
- 64% of all R&D partner FTEs* are in Africa

*Staff in full-time equivalents